| R2 Medical Centers, Llc | |
|
2072b E Commercial Ave Lowell IN 46356-2116 | |
| (801) 494-9769 | |
| (219) 696-6880 |
| Full Name | R2 Medical Centers, Llc |
|---|---|
| Speciality | General Practice |
| Location | 2072b E Commercial Ave, Lowell, Indiana |
| Authorized Official Name and Position | Casey H Walker (PRESIDENT/MEMBER) |
| Authorized Official Contact | 2196968916 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| R2 Medical Centers, Llc 2072b E Commercial Ave Lowell IN 46356-2116 Ph: (801) 494-9769 | R2 Medical Centers, Llc 2072b E Commercial Ave Lowell IN 46356-2116 Ph: (801) 494-9769 |
| NPI Number | 1376054460 |
|---|---|
| Provider Enumeration Date | 10/17/2017 |
| Last Update Date | 08/17/2020 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376054460 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | (* (Not Available)) | Primary |
News Archive
Some studies indicate that early life exposure to pollutants such as PCBs and phthalates can predispose people to disease. Now environmental scientist Alicia Timme-Laragy at the University of Massachusetts Amherst has received a five-year, $1.7 million grant from the National Institute of Environmental Health Sciences for a multi-level study of early life exposure to environmental contaminants and aberrant pancreas development, which may predispose one to diabetes.
The largest genome-wide association study to date of the malaria parasite Plasmodium falciparum unveils a complex genetic architecture that enables the parasite to develop resistance to our most effective antimalarial drug, artemisinin. The results could help to improve early detection of emerging artemisinin resistance.
Most postmenopausal women with small breast tumors don't need chemotherapy to reduce their recurrence risk after lumpectomy.
MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.
The development of new generic versions of expensive biologic drugs "faces a long, tough road to realization" because the complex generics "will likely face tough regulatory scrutiny, as well as high development and marketing costs," the Wall Street Journal reports.
› Verified 9 days ago
Randall Hile Md Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1020 E Commercial Ave, Lowell, IN 46356 Phone: 219-696-3052 Fax: 219-696-4629 | |
We Care 4-u Family Medicine Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 111 Deanna Dr, Lowell, IN 46356 Phone: 219-552-5544 |